Siseles 1995.

Methods	Randomised open‐label controlled trial
Participants	30 postmenopausal women ≥ 1 year postmenopausal and reporting hot flushes and other menopausal symptoms (but otherwise healthy). Age range 48 to 62 years
Interventions	Tibolone 2.5 mg/d Conjugated oestrogens 0.625 mg/d continuously, medroxyprogesterone 5 mg/d sequentially for 12 days of each 28‐day cycle Administered for six 28‐day cycles
Outcomes	Hot flushes, sweating, sleeplessness, irregular bleeding, endometrial hyperplasia
Notes	Menopausal symptoms measured through Kupperman Index but results available only as a graph Bleeding not evaluable because insufficient information provided Timing: June to Dec 1990 Trial location: Argentina Multi‐centre: no; single site
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information provided
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Not specified, but given the nature of the outcome of interest (endometrial hyperplasia), its evaluation is likely to be "objective"
Incomplete outcome data (attrition bias) All outcomes	High risk	6/30 patients excluded from final analyses
Selective reporting (reporting bias)	Unclear risk	Study protocol not available
Conflict of interest	High risk	Financed by drug manufacturer. Study authors' conflicts of interest not stated